Fahr’s disease is a rare neurological condition in which calcium gradually builds up in deep structures of the brain, particularly the basal ganglia. These deposits damage surrounding tissue over time, leading to movement problems, cognitive decline, and psychiatric symptoms. The condition typically appears between the ages of 40 and 60, though it can surface as early as childhood or adolescence.
The term can be confusing because “Fahr’s disease” and “Fahr’s syndrome” are often used interchangeably but refer to different situations. Fahr’s disease is the genetic or idiopathic form, now formally called primary familial brain calcification. Fahr’s syndrome describes the same pattern of brain calcification, but caused by an underlying metabolic problem like a parathyroid disorder, vitamin D deficiency, or kidney failure. The distinction matters because secondary causes are sometimes treatable.
What Happens in the Brain
Calcium deposits accumulate symmetrically in specific brain regions. The globus pallidus, a structure deep within the basal ganglia involved in controlling voluntary movement, is typically affected first. Over time, calcification spreads to nearby structures including the caudate nucleus, the lentiform nucleus, the thalamus, and the dentate nuclei in the cerebellum. Subcortical white matter can also be involved.
The underlying problem in many genetic cases involves the body’s ability to regulate phosphate in brain tissue. The most commonly mutated gene, SLC20A2, produces a protein that transports phosphate across cell membranes in neurons. When this protein doesn’t work properly, phosphate levels become dysregulated, and calcium-phosphate deposits form in and around blood vessel walls and brain tissue. Other implicated genes, including PDGFRB and PDGFB, affect signaling pathways that help maintain the blood-brain barrier and the health of cells lining blood vessels in the brain.
Genetic Causes and Inheritance
At least six genes have been linked to primary familial brain calcification. Mutations in SLC20A2 account for roughly 40 percent of genetically confirmed cases, making it the most common cause. PDGFRB mutations explain about 10 percent. Other associated genes include PDGFB, XPR1, MYORG, and JAM2. Some of these follow autosomal dominant inheritance, meaning a single copy of the mutated gene from one parent is enough to cause disease. Others, like MYORG, follow an autosomal recessive pattern, requiring mutations from both parents.
The condition is more common than previously believed. Early estimates placed prevalence at roughly 1 in 1 million people, but more recent genetic studies suggest the true figure could be far higher. A 2013 analysis estimated a minimal prevalence of about 2.1 per 1,000 people, and a 2019 Chinese cohort study revised that estimate upward to 6.6 per 1,000. Many of these individuals may have calcification visible on brain imaging without obvious symptoms, which likely explains why the condition has historically been underdiagnosed.
Symptoms and How They Progress
The most common initial presentation involves movement problems resembling Parkinson’s disease. This extrapyramidal syndrome, as neurologists call it, can include tremor, rigidity, slowness of movement, and an unsteady gait. Other motor symptoms range widely: involuntary muscle contractions (dystonia), jerking movements (myoclonus), seizures, difficulty with coordination (ataxia), abnormal facial movements, and speech impairment.
Psychiatric and cognitive symptoms are also common and sometimes appear before motor problems do. These include depression, personality changes, mania, and frontal lobe dysfunction, which affects planning, decision-making, and impulse control. Some patients develop significant cognitive decline over years. The psychiatric symptoms can be prominent enough that a person initially receives a psychiatric diagnosis before the brain calcifications are discovered on imaging.
The prognosis varies enormously from person to person. Some individuals with extensive calcification on brain scans have minimal symptoms, while others with seemingly modest deposits experience significant disability. There is no reliable way to predict how quickly or severely the disease will progress based on the size or location of the calcium deposits alone.
How It’s Diagnosed
A CT scan of the head is the primary diagnostic tool. CT is far more sensitive than MRI for detecting calcium, and the pattern it reveals is fairly distinctive: dense, symmetric calcification in the basal ganglia, thalamus, and cerebellar dentate nuclei. The globus pallidus is almost always involved.
Seeing calcification on a scan is only the first step. To confirm Fahr’s disease rather than Fahr’s syndrome, doctors need to rule out secondary causes. This means checking blood calcium, phosphate, and parathyroid hormone levels to exclude hypoparathyroidism and related conditions. Kidney function and vitamin D levels are also assessed. If metabolic causes are excluded, the diagnosis rests on the imaging pattern combined with clinical symptoms, family history, and ideally genetic testing confirming a mutation in one of the known causative genes.
Suggested diagnostic criteria include: a confirmed genetic abnormality or positive family history consistent with known inheritance patterns, typical age of onset between 40 and 60, calcification in the characteristic distribution that progresses over time, and exclusion of all secondary causes.
Treatment and Symptom Management
No treatment currently stops or reverses the calcification process. Management focuses on controlling symptoms as they arise. Seizures are treated with anti-seizure medications. Depression, anxiety, and obsessive-compulsive behaviors respond to standard antidepressant therapy. Movement disorders can be managed with medications typically used for conditions like Parkinson’s disease.
The approach is highly individualized because the symptom profile varies so much between patients. Someone whose primary problem is depression and anxiety will have a very different treatment plan than someone dealing mainly with tremor and gait instability. Regular neurological follow-up helps track progression and adjust medications over time.
A Drug Trial Targeting Brain Calcification
One ongoing clinical trial is testing whether a bone-metabolism drug called etidronate, a bisphosphonate normally used for osteoporosis, can slow or halt calcification in the brain. The CALCIFADE trial, which began recruiting in 2023 and is expected to run through 2027, is a randomized, placebo-controlled study investigating whether the drug can preserve cognitive function, maintain mobility, and stabilize calcification as measured on repeat CT scans. The rationale is that bisphosphonates inhibit abnormal calcium deposition in blood vessels and soft tissues, and this effect might extend to the brain. Results are still years away, but this represents the first rigorous attempt at a disease-modifying treatment for the condition.